Rolf Turk

7PUBLICATIONS
28CO-AUTHORS
Software quality, processes and metricsCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical molecular engineering of nucleic acids and proteinsNeurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 11, 2026
UNCOVERseq enables sensitive and controlled gene editing off-target nomination across CRISPR-Cas modalities and systems.

|Oct 05, 2023
An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies.

Jingyu Xiang, Jessica M Devenport, Alun J Carter

|Oct 01, 2021
Optimized design parameters for CRISPR Cas9 and Cas12a homology-directed repair.

Mollie S Schubert, Bernice Thommandru, Jessica Woodley

|Jun 24, 2021
AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines.

Liyang Zhang, John A Zuris, Ramya Viswanathan

|Aug 08, 2018
A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells.

Christopher A Vakulskas, Daniel P Dever, Garrett R Rettig

|Aug 02, 2017
Dystroglycan Maintains Inner Limiting Membrane Integrity to Coordinate Retinal Development.

Reena Clements, Rolf Turk, Kevin P Campbell

Pageof 2

Frequent Collaborators

4 joint publications

Mark Behlke

3 joint publications

Gavin L Kurgan

3 joint publications

Christopher A Vakulskas

3 joint publications

Garrett Rettig